Clinical prognostic factors associated with outcome in patients with renal cell cancer with prior tyrosine kinase inhibitors or immunotherapy treated with everolimus

Amato, Robert J.; Flaherty, Amber; Zhang, Yufeng; Ouyang, Fangqian; Mohlere, Virginia

doi:10.1016/j.urolonc.2013.09.008

Cited by 22 publications

(9 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Evidences have showed that everolimus plus exemestane showed efficient anticancer therapy in postmenopausal patients with hormone receptor-positive [HR(+)] breast cancer, which further supported the use of everolimus plus exemestane in this patient population ( 11 ). Clinical prognostic factors associated with therapeutic efficacy for patients after received everolimus immunotherapy prolonged the overall survival determined by available clinical parameters ( 12 ). A study has indicated that everolimus was generally well tolerated in elderly patients with HR(+) advanced breast cancer ( 13 ).…”

Section: Introductionmentioning

confidence: 99%

Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway

Zhen

et al. 2018

Mol Med Report

View full text Add to dashboard Cite

Breast cancer is one of the most prevalent malignancies and the leading cause of cancer-associated mortality in women worldwide and in China. Everolimus (C53H83NO14) is an efficient anti-cancer drug for breast cancer which targets mammalian target of rapamycin (mTOR). The present study investigated the inhibitory effects of everolimus on breast cancer cells and an MCF-7-bearing mouse model. The potential mechanism of the everolimus-mediated decrease in growth and aggressiveness of breast cancer cells was reported. Results demonstrated that everolimus significantly inhibited breast cancer cell growth, migration and invasion. It was demonstrated that everolimus induced apoptosis through decreasing B cell lymphoma (Bcl)-2 and Bcl-w and increasing caspase-3 and caspase-8 expression levels in breast cancer cells. It was observed that everolimus decreased phosphoinositide 3-kinase (PI3K), protein kinase B (AKT) and mTOR expression levels in breast cancer cells. Results additionally demonstrated that PI3 K overexpression prevented that everolimus-mediated inhibition of growth and aggressiveness in MCF-7 cells. In vivo assays demonstrated that everolimus treatment markedly inhibited tumor growth in the MCF-7 bearing mouse model. Overall, these data indicate that everolimus inhibits growth and aggressiveness of breast cancer cells through the PI3K/AKT/mTOR signaling pathways, suggesting the PI3K/AKT/mTOR signaling pathway may act as a therapeutic target for the treatment of human cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway

Zhen

et al. 2018

Mol Med Report

View full text Add to dashboard Cite

show abstract

“…The results suggest that patients with bone metastases only may retrieve longterm benefit from everolimus. The efficacy and safety of everolimus has also been examined in other advanced cancers with bone metastasis, including renal cell carcinoma, non-small cell lung carcinoma and prostate carcinoma [97][98][99]. Compared to everolimus alone, the combination of everolimus and ZOL significantly reduces bone resorption markers and prolongs tumour control in renal cell carcinoma patients with bone metastases [97].…”

Section: Mammalian Target Of Rapamycin (Mtor) Inhibitorsmentioning

confidence: 99%

“…The efficacy and safety of everolimus has also been examined in other advanced cancers with bone metastasis, including renal cell carcinoma, non-small cell lung carcinoma and prostate carcinoma [97][98][99]. Compared to everolimus alone, the combination of everolimus and ZOL significantly reduces bone resorption markers and prolongs tumour control in renal cell carcinoma patients with bone metastases [97]. Similar synergistic effects of everolimus and ZOL in delaying bone metastasis and prolonging OS were seen in patients with advanced non-small cell lung carcinoma and bone metastases [99].…”

Section: Mammalian Target Of Rapamycin (Mtor) Inhibitorsmentioning

confidence: 99%

Bone-Targeted Therapies in Cancer-Induced Bone Disease

Sousa

Clézardin

2017

Calcif Tissue Int

View full text Add to dashboard Cite

Cancer-induced bone disease is a major source of morbidity and mortality in cancer patients. Thus, effective bone-targeted therapies are essential to improve disease-free, overall survival and quality of life of cancer patients with bone metastases. Depending of the cancer-type, bone metastases mainly involve the modulation of osteoclast and/or osteoblast activity by tumour cells. To inhibit metastatic bone disease effectively, it is imperative to understand its underlying mechanisms and identify the target cells for therapy. If the aim is to prevent bone metastasis, it is essential to target not only bone metastatic features in the tumour cells, but also tumour-nurturing bone microenvironment properties. The currently available bone-targeted agents mainly affect osteoclasts, inhibiting bone resorption (e.g. bisphosphonates, denosumab). Some agents targeting osteoblasts begin to emerge which target osteoblasts (e.g. romosozumab), activating bone formation. Moreover, certain drugs initially thought to target only osteoclasts are now known to have a dual action (activating osteoblasts and inhibiting osteoclasts, e.g. proteasome inhibitors). This review will focus on the evolution of bone-targeted therapies for the treatment of cancer-induced bone disease, summarizing preclinical and clinical findings obtained with anti-resorptive and bone anabolic therapies.

show abstract

“…Thus far, however, no definitive results have been shown, while some in need of prospective validation [76]. …”

Section: Reviewmentioning

confidence: 99%

An update on current management of advanced renal cell cancer, biomarkers, and future directions

Zhi¹,

Kim²

2014

J Cancer Ther Res

View full text Add to dashboard Cite

Clinical prognostic factors associated with outcome in patients with renal cell cancer with prior tyrosine kinase inhibitors or immunotherapy treated with everolimus

Cited by 22 publications

References 14 publications

Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway

Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway

Bone-Targeted Therapies in Cancer-Induced Bone Disease

An update on current management of advanced renal cell cancer, biomarkers, and future directions

Contact Info

Product

Resources

About